Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

797 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH, Seo JH, Park JH, Seong MK, Park KU, Kim MK, Chang M, Koh SJ, Lee MH, Lim ST, Yoo YB, Oh SY, Kim SH, Ahn KY, Park TH, Ju H, Baek EH, Kim S, Kim N, Lee E, Kim TH. Park MH, et al. Among authors: park th. Expert Opin Biol Ther. 2024 Apr;24(4):305-312. doi: 10.1080/14712598.2024.2334386. Epub 2024 Apr 25. Expert Opin Biol Ther. 2024. PMID: 38664937
A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.
Jo JC, Jeon Y, Kim D, Yang DH, Lee WS, Choi YS, Yi JH, Yoon DH, Kong JH, Choe JY, Kim S, Ahn K, Park T, Ju H, Kwon S, Cho SG. Jo JC, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):737-747. doi: 10.1080/14712598.2023.2177101. Epub 2023 Mar 8. Expert Opin Biol Ther. 2023. PMID: 36757373
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
Stebbing J, Baranau Y, Baryash V, Moiseyenko V, Boliukh D, Antone N, Manikhas A, Chornobai A, Park T, Baek EH, Lee J, Choi J, Kim N, Ahn K, Lee SJ, Kim S. Stebbing J, et al. BioDrugs. 2023 May;37(3):433-440. doi: 10.1007/s40259-023-00582-w. Epub 2023 Mar 7. BioDrugs. 2023. PMID: 36881323 Free PMC article. Clinical Trial.
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
Verschraegen C, Andric Z, Moiseenko F, Makharadze T, Shevnya S, Oleksiienko A, Yañez Ruiz E, Kim S, Ahn K, Park T, Park S, Ju H, Ohe Y. Verschraegen C, et al. BioDrugs. 2022 Nov;36(6):749-760. doi: 10.1007/s40259-022-00552-8. Epub 2022 Sep 28. BioDrugs. 2022. PMID: 36169807 Free PMC article. Clinical Trial.
Azimuthal Angle Correlations of Muons Produced via Heavy-Flavor Decays in 5.02 TeV Pb+Pb and pp Collisions with the ATLAS Detector.
Aad G, Abbott B, Abeling K, Abicht NJ, Abidi SH, Aboulhorma A, Abramowicz H, Abreu H, Abulaiti Y, Acharya BS, Adam Bourdarios C, Adamczyk L, Addepalli SV, Addison MJ, Adelman J, Adiguzel A, Adye T, Affolder AA, Afik Y, Agaras MN, Agarwala J, Aggarwal A, Agheorghiesei C, Ahmad A, Ahmadov F, Ahmed WS, Ahuja S, Ai X, Aielli G, Aikot A, Ait Tamlihat M, Aitbenchikh B, Aizenberg I, Akbiyik M, Åkesson TPA, Akimov AV, Akiyama D, Akolkar NN, Aktas S, Al Khoury K, Alberghi GL, Albert J, Albicocco P, Albouy GL, Alderweireldt S, Alegria ZL, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi F, Algren M, Alhroob M, Ali B, Ali HMJ, Ali S, Alibocus SW, Aliev M, Alimonti G, Alkakhi W, Allaire C, Allbrooke BMM, Allen JF, Allendes Flores CA, Allport PP, Aloisio A, Alonso F, Alpigiani C, Alvarez Estevez M, Alvarez Fernandez A, Alves Cardoso M, Alviggi MG, Aly M, Amaral Coutinho Y, Ambler A, Amelung C, Amerl M, Ames CG, Amidei D, Amor Dos Santos SP, Amos KR, Ananiev V, Anastopoulos C, Andeen T, Anders JK, Andrean SY, Andreazza A, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Anulli F, Aoki M, Aoki T, Aparisi Pozo JA, Aparo MA, Aperio Bella L, A… See abstract for full author list ➔ Aad G, et al. Among authors: park th. Phys Rev Lett. 2024 May 17;132(20):202301. doi: 10.1103/PhysRevLett.132.202301. Phys Rev Lett. 2024. PMID: 38829073
Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT/CHANCE Trial Treatment.
Kim JT, Lee JS, Kim H, Kim BJ, Lee KJ, Park JM, Kang K, Lee SJ, Kim JG, Cha JK, Kim DH, Park TH, Lee K, Lee J, Hong KS, Cho YJ, Park HK, Lee BC, Yu KH, Oh MS, Kim DE, Choi JC, Kwon JH, Kim WJ, Shin DI, Yum KS, Sohn SI, Hong JH, Lee SH, Park MS, Ryu WS, Park KY, Lee J, Saver JL, Bae HJ. Kim JT, et al. Among authors: park th. J Am Heart Assoc. 2024 May 21;13(10):e033611. doi: 10.1161/JAHA.123.033611. Epub 2024 May 18. J Am Heart Assoc. 2024. PMID: 38761083 Free article.
797 results